Peripheral Neuroblastic Tumors

Clinical Endocrine Oncology: Second Edition

Volumn , Issue , 2009, Pages 360-369

  De Bernardi, Bruno ^a   Pistoia, Vito ^a   Gambini, Claudio ^a   Granata, Claudio ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Claude Bernard Horner syndrome; Fetal alcohol syndrome; Ganglioneuroblastoma; Ganglioneuroma; Neuroblastoma; Primitive cells of neural crest

Indexed keywords

EID: 70350004474     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444300222.ch47     Document Type: Chapter

References (33)

1. Castleberry RP. Neuroblastoma. Eur. J. Cancer 1997;33:1430-1437.
2. De Bernardi B, Milanaccio C, Occhi M. Neuroblastoma. In Sheaves R, Jenkins PJ, Wass JAH (eds). Clinical Endocrine Oncology. Oxford: Blackwell Science, 1997306-311.
3. Caron HN, Pearson ADJ. Neuroblastoma. In Voute PA, Barrett A, Stevens MCG, Caron HN (eds). Cancer in Children, 5th edn. Oxford: Oxford University Press, 2005337-352.
4. Brodeur GM, Maris JM. Neuroblastoma. In Pizzo PA, Poplack DG (eds). Principles and Practice of Pediatric Oncology, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2002895-938.
5. Kaneko Y, Kanda N, Maseki N, et al. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study. J. Clin. Oncol. 1990;8:2005-2013.
6. Tsubono Y, Hisamichi S. A halt to neuroblastoma screening in Japan. N. Engl. J. Med. 2004;350:2010-2011.
7. Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J. Natl Cancer Inst. 1984;73:405-416.
8. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer 1999;86:364-372.
9. Tonini GP, Boni L, Pession A, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J. Clin. Oncol. 1997;15:85-93.
10. Caron H, van Sluis P, Buschman R, et al. Alleic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N. Engl. J. Med. 1996;334:225-230.
11. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med. 1999;340:1954-1961.
12. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma. A Pediatric Oncology Group study. J. Clin. Oncol. 1991;9:581-591.
13. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 2000;6:529-535.
14. Conte M, Parodi S, De Bernardi B, et al. Neuroblastoma in adolescents: the Italian experience. Cancer 2006;106:1409-1417.
15. De Bernardi B, Pianca C, Pistamiglio P, et al. Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J. Clin. Oncol. 2001;19:183-190.
16. Gambini C, Conte M, Bernini G, et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch. 2003;442:555-562.
17. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 1993;11:1466-1477.
18. Claudiani F, Stimamiglio P, Bertolazzi L, et al. Radioiodinated metaiodobenzylguanidine in the diagnosis of childhood neuroblastoma. Q. J. Nucl. Med. 1995;39:21-24.
19. La Quaglia MP. Surgical management of neuroblastoma. Semin. Pediatr. Surg. 2001;10:132-139.
20. Halperin EC, Cox EB. Radiation therapy in the management of neuroblastoma: the Duke University Medical Center experience 1967-1984. Int. J. Radiat. Oncol. Biol. Phys. 1986;12:1829-1837.
21. Garaventa A, Bellagamba O, Lo Piccolo MS, et al. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br. J. Cancer 1999;81:1378-1384.
22. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J. Clin. Oncol. 2003;21:1592-1601.
23. Garaventa A, Luksch R, Biasotti S et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer 2003;98:2488-2494.
24. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 1999;341:1165-1173.
25. Garaventa A, Luksch R, Lo Piccolo MS, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin. Cancer Res. 2003;9:2032-2039.
26. Villablanca JG, Krailo MD, Ames MM, et al. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J. Clin. Oncol. 2006;24:3423-3430.
27. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol. 1998;16:2169-2180.
28. Neal ZC, Yang JC, Rakhmilevich AL, et al. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin. Cancer Res. 2004;10:4839-4847.
29. Tonini GP, Pistoia V. Molecularly guided therapy of neuroblastoma: a review of different approaches. Curr. Pharm. Dev. 2006;12:2303-2317.
30. Bowman LC, Grossmann M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum. Gene Ther. 1998;9:1303-1311.
31. Beppu K, Jaboine J, Merchant MS, et al. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J. Natl Cancer Inst. 2004;96:46-55.
32. Raffaghello L, Pagnan G, Pastorino F, et al. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Lett. 2003;197:151-155.
33. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 2003;3:203-216.